Acadia Pharmaceuticals (ACAD) Liabilities and Shareholders Equity (2010 - 2026)

Acadia Pharmaceuticals' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $1.6 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 41.76% year-over-year to $1.6 billion; the TTM figure through Mar 2026 stood at $5.7 billion (up 35.97% YoY), while the FY2025 annual figure was $1.6 billion, up 31.69% from the prior year.
• Liabilities and Shareholders Equity was $1.6 billion for Q1 2026 at Acadia Pharmaceuticals, up from $1.6 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.6 billion in Q1 2026 to a low of $587.8 million in Q4 2022.
• Historically, Liabilities and Shareholders Equity has averaged $935.2 million across 5 years, with a median of $855.1 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity declined 17.34% in 2022, then jumped 58.59% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $587.8 million in 2022, then grew by 27.41% to $749.0 million in 2023, then surged by 58.59% to $1.2 billion in 2024, then jumped by 31.69% to $1.6 billion in 2025, then increased by 2.62% to $1.6 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.6 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.